`
`Organization Disclosures
`
`A A A+
`
`Organization Disclosures
`Click here to view individual disclosures
`
`Accelerated Cure
`2009
`Events $300,019
`Individual Giving $698,523
`Pharmaceutical Support $124,125 (individual support listed as
`follows)
`Biogen Idec $60,000
`EMD Serono $40,000
`Genentech $10,050
`Teva Neuroscience $10,000
`Pfizer $4,075
`Other Corporate/Foundation Support $3,910,191
`Total $5,032,858
`
`American Academy of Neurology
`
`2010
`Below is a breakdown of industry contribution towards the
`consolidated revenue of the Academy (American Academy of
`Neurology, American Academy of Neurology Institute, American
`Academy of Neurology Foundation, AAN Enterprises, Inc.). Industry
`includes forprofit entities that develop, produce, market, or
`distribute drugs, devices, services or therapies used to diagnose,
`treat, monitor, manage, and alleviate health conditions (e.g.,
`pharmaceutical and medical device/software manufacturers and
`other forprofit health services/product providers). Industry does not
`include nonprofit entities, entities outside of the healthcare sector,
`or entities through which physicians provide clinical services
`directly to patients (e.g., hospitals, medical centers, publishers,
`foundations, recruiters, insurance providers).
`2010 Industry Contribution
`Total Industryrelated Revenue: $5,482,769
`Percentage of Total Academy Revenue: 17%*
`http://www.ms-coalition.org/emergingtherapies/disclosures/organization-disclosures
`
`Main Menu
`
`Home
`Disclosures
`Organization Disclosures
`Individual Disclosures
`Medications
`Disease Modifying
`Alemtuzumab (Lemtrada)
`Dimethyl Fumarate
`[formerly called BG12]
`(Tecfidera)
`Fingolimod (Gilenya)
`Pegylated Interferon Beta
`1A (Plegridy)
`Teriflunomide (Aubagio)
`Symptom Management
`Dalfampridine (Ampyra)
`Dextromethorphan
`hydrobromide/Quinidine
`sulfate (Nuedexta)
`OnabotulinumtoxinA
`(Botox)
`Updated Information on
`Approved Treatments
`Tools and Resources
`
`1/9
`
`MYLAN PHARMS. INC. EXHIBIT 1128 PAGE 1
`
`
`
`3/6/2016
`
`Organization Disclosures
`
`Educational Grants: $857,416
`Sponsorship: $1,027,800
`Charitable Contributions (Foundation): $83,000
`Corporate Roundtable Membership Dues (Foundation):
`$690,000
`Exhibit Space: $2,053,500
`Advertising: $771,053
`Companies Contributing over $100,000 in 2010:
`Biogen Idec
`TEVA Neuroscience, Inc.
`Pfizer Inc.
`Allergan, Inc.
`EMD Serono, Inc.
`UCB, Inc.
`Acorda Therapeutics, Inc.
`Novartis Pharmaceuticals
`Bayer HealthCare Pharmaceuticals
`Lilly USA, LLC
`Sunovion Pharmaceuticals Inc. (formerly Sepracor)
`Merz Pharmaceuticals, LLC
`Forest Pharmaceuticals, Inc.
`Lundbeck Inc.
`
`*Based on forecasted amounts. 2010 audit not yet complete.
`
`2009
`Below is a breakdown of industry contribution towards the
`consolidated revenue of the Academy (American Academy of
`Neurology, American Academy of Neurology Institute, American
`Academy of Neurology Foundation, AAN Enterprises, Inc.).
`Industry includes forprofit entities that develop, produce,
`market, or distribute drugs, devices, services or therapies used
`to diagnose, treat, monitor, manage, and alleviate health
`conditions (e.g., pharmaceutical and medical device/software
`manufacturers and other forprofit health services/product
`providers). Industry does not include nonprofit entities, entities
`outside of the healthcare sector, or entities through which
`physicians provide clinical services directly to patients (e.g.,
`hospitals, medical centers, publishers, foundations, recruiters,
`insurance providers).
`
`2009 Industry Contribution
`Total Industryrelated Revenue: $5,538,907
`Percentage of Total Academy Revenue: 18%
`Educational Grants: $944,483
`Sponsorship: $1,231,230
`
`http://www.ms-coalition.org/emergingtherapies/disclosures/organization-disclosures
`
`2/9
`
`MYLAN PHARMS. INC. EXHIBIT 1128 PAGE 2
`
`
`
`3/6/2016
`
`Organization Disclosures
`
`Charitable Contributions (Foundation): $
`Corporate Roundtable Membership Dues (Foundation):
`$450,000
`Exhibit Space: $2,426,700
`Advertising: $486,494
`Companies Contributing over $100,000 in 2009:
`Biogen Idec
`TEVA Neuroscience, Inc.
`UCB, Inc.
`Allergan, Inc.
`Pfizer Inc.
`Bayer HealthCare Pharmaceuticals
`Acorda Therapeutics, Inc.
`EMD Serono, Inc.
`Lilly USA, LLC
`Lundbeck Inc.
`Boehringer Ingelheim Pharmaceuticals, Inc.
`OrthoMcNeil Neurologics, Inc.
`Cephalon, Inc.
`Forest Pharmaceuticals, Inc.
`Questcor Pharmaceuticals, Inc.
`Merck
`
`Americas Committee for Treatment and Research in
`Multiple Sclerosis
`
`ACTRIMS is a community of leaders dedicated to treatment and
`research in multiple sclerosis, dissemination of knowledge and
`education, and collaboration among disciplines. It also seeks to
`foster clinical and research talent among young researchers.
`ACTRIMS is dedicated to providing leadership in the field of
`multiple sclerosis and other demyelinating diseases.
`
`ACTRIMS is a boarddirected, nonmembership organization.
`Founded in 1995 ACTRIMS was formally incorporated in 2009
`and was recognized by the IRS as a tax exempt organization
`under section 501(c)(3) of the Internal Revenue Code. The
`present principle activity of ACTRIMS is to provide an annual
`educational meeting for the presentation, discussion and debate
`of current topics in MS clinical and basic research. Participants
`include clinicians, clinical scientists, and basic researchers. In
`select years since 1999, ACTRIMS has held joint meetings with
`its European counterpart, ECTRIMS. Sources of revenue
`include registration fees, sponsorship, exhibit hall fees and
`advertising.
`
`http://www.ms-coalition.org/emergingtherapies/disclosures/organization-disclosures
`
`3/9
`
`MYLAN PHARMS. INC. EXHIBIT 1128 PAGE 3
`
`
`
`3/6/2016
`
`Organization Disclosures
`
`2010
`ACTRIMS received educational grants in support of its annual
`meeting. Contributors included the following:
`Advir $5,000
`Genzyme $5,000
`Society of Canada $14,625
`Teva Neuroscience $25,000
`
`Can Do Multiple Sclerosis
`Can Do Multiple Sclerosis is an innovative provider of lifestyle
`empowerment programs for people with MS and their support
`partners who want to overcome the challenges of their disease
`and learn what is possible with MS. Can Do MS envisions a
`world in which all people impacted by MS maximize their
`potential, improving their quality of life. It is our mission to
`lead the way with comprehensive programs that empower
`people and families living with MS to transform and improve
`their quality of life. Achieving our vision requires a diverse base
`of support. Our sources of support include the following:
`
`Pharmaceutical Support: Pharmaceutical companies provide
`financial support for our lifestyle empowerment programs and
`patient and professional education. Total pharmaceutical
`support is 48% ($727,076 in 2013) of our total annual revenue.
`
`Individual Giving: Generous individual donors also provide
`funding for our lifestyle empowerment programs. Donations at
`all giving levels contribute approximately 27% ($412,461 in
`2013) to our annual revenue.
`
`Foundation Support: Foundation support is 17% ($255,275 in
`2013) of our annual revenue. Many local and national
`foundations also support our programs and assist in our
`bringing them to various areas around the country.
`
`Corporate support of approximately 10% ($152,178 in 2013)
`added to our total revenue. Corporations across the country
`support our mission through direct financial support, cause
`related partnerships, and inkind goods and services.
`
`Special Events: Can Do MS benefits from special events held
`throughout the year which raise funds needed to support our
`mission. The major fundraising events in 2013 were the Vertical
`Express for Can Do MS event series (at Crystal Mountain, WA;
`Schweitzer Mountain, ID; and Squaw Valley, CA), the Alpen
`Wine Festival (Squaw Valley, CA), the Cut N Slice Golf
`Tournament (Beaver Creek, CO), Can Do Day (Eagle County,
`CO), and the Annual Autumn Benefit (New York City).
`
`http://www.ms-coalition.org/emergingtherapies/disclosures/organization-disclosures
`
`4/9
`
`MYLAN PHARMS. INC. EXHIBIT 1128 PAGE 4
`
`
`
`3/6/2016
`
`Organization Disclosures
`Additionally, Can Do MS benefits from events conducted by
`supporters of our mission all over the country. These events
`include an endurance run, fundraising dinners, a golf event,
`among others. Approximately 41% ($621,700) of the total 2013
`revenue of Can Do MS was raised by special events.
`
`Consortium of Multiple Sclerosis Centers
`2010
`
`The Consortium of Multiple Sclerosis Centers is the grateful
`recipient of grants and other support from: Acorda Therapeutics,
`Inc., Allergan, Inc., Bayer HealthCare Pharmaceuticals, Inc.,
`BiogenIdec, EMD Serono, Novartis Pharmaceuticals, Inc., and
`TEVA Pharmaceuticals U.S.A.
`
`International Organization of Multiple Sclerosis Nurses
`2010
`
`The International Organization of Multiple Sclerosis Nurses is
`the grateful recipient of grants and other support from: Acorda
`Therapeutics, Inc., Bayer HealthCare Pharmaceuticals, Inc.,
`BiogenIdec and TEVA Pharmaceuticals U.S.A.
`
`Multiple Sclerosis Association of America
`
`$234,614
`$449,820
`
`$15,000
`$395,426
`$45,500
`$330,495
`
`2013
`Pharmaceutical Industry Supporters:
`Acorda Therapeutics Inc.
`$139,300
`Allergan, Inc.
`$111,489
`Bayer Healthcare
`$60,940
`Pharmaceuticals
`Biogen Idec
`EMD Serono, Inc. and Pfizer,
`Inc.
`Genentech, Inc.
`Genzyme
`Medtronic Foundation
`Novartis Pharmaceuticals
`Corporation
`Questcor Pharmaceuticals,
`Inc.
`Teva Pharmaceuticals
`
`$340,740
`
`$384,046
`
`2010
`Total Pharmaceutical Revenue:
`http://www.ms-coalition.org/emergingtherapies/disclosures/organization-disclosures
`
`$2.74 M
`
`5/9
`
`MYLAN PHARMS. INC. EXHIBIT 1128 PAGE 5
`
`
`
`3/6/2016
`
`Organization Disclosures
`
`0.2 M
`
`Percentage of Total Revenue (25%)
`Sponsorships
`1.6 M
`Advertising
`0.03 M
`Grants
`0.9 M
`Total Contribution w/out MS product in the Market
`in 2010:
`Total Contribution with MS product in the Market
`in 2010:
`Bayer
`Biogen
`Genentech
`Acorda
`Serono
`Teva
`
`0.11 M
`0.03 M
`0.13 M
`0.11 M
`1.20 M
`0.95 M
`
`The Multiple Sclerosis Foundation
`2010
`The Multiple Sclerosis Foundation is a servicebased, publicly
`funded 501(c)3 organization that strives to provide a
`comprehensive approach to helping people with MS maintain
`their health and wellbeing. We offer programming and support
`to keep them selfsufficient and their homes safe, while our
`educational programs heighten public awareness and promote
`understanding about the disease.
`
`Our resources assist people who have MS, their families and
`caregivers, regional support groups, and healthcare
`professionals. Access to our programs and services is available
`through our interactive web site or our national, tollfree helpline
`staffed by caring caseworkers and peer counselors. Our priority
`is to serve with empathy, resourcefulness and responsibility.
`
`All MSF services, as well as information, literature and
`subscriptions to our publications are provided free of charge.
`The MSF neither sells memberships nor requires participation in
`fundraising activities by individuals or support groups.
`
`To achieve this mission, the MSF receives support from the
`following sources:
`
`*Individual giving: 83.1 percent. The generosity of individual
`donors provides the majority of our annual revenue.
`
`*Pharmaceutical grants (educational and charitable): 8.7
`percent. Grants have been received from Teva Neuroscience,
`http://www.ms-coalition.org/emergingtherapies/disclosures/organization-disclosures
`
`6/9
`
`MYLAN PHARMS. INC. EXHIBIT 1128 PAGE 6
`
`
`
`3/6/2016
`
`Organization Disclosures
`Biogen Idec, EMD Serono, Acorda Therapeutics, Novartis,
`Bayer and Genentech.
`
`*Other: 8.2 percent. This segment includes funds from
`businesses and corporations outside of the pharmaceutical
`industry as well as matching gifts and special events.
`
`Additionally, the MSF continues to advance partnerships and
`develop initiatives with other organizations, educational
`institutions, MS Centers, healthcare professionals, and
`individuals who share our commitment to learning more about
`MS as well as improving the quality of life for those who live with
`the disease.
`
`National Multiple Sclerosis Society
`2009
`We all share a vision for the future: A world free of multiple
`sclerosis. Achieving our mission, and ultimately ending MS
`forever, requires reliance on a broad base of support. Each
`year, hundreds of thousands of people give generously to the
`Society. In fact, the large majority of our funds come from
`people making contributions of less than $100. Our sources of
`support include the following:
`
`Special Events: The Society offers hundreds of special events
`throughout the year to engage participants and fundraisers
`critical to supporting the mission. Approximately 65% ($135
`million in 2009) of the Society's total annual revenue is raised
`through special events, including Bike MS and Walk MS events.
`
`Individual Giving: Generous individual donors provide a
`substantial source of funding toward the mission. Donations at
`all giving levels contribute approximately 31% ($65 million in
`2009) of the Society's total annual revenue.
`
`Pharmaceutical Support: Pharmaceutical organizations
`provide financial support for client programs and education,
`professional and clinical development, and event support. In
`total, pharmaceutical support is 5% of the Society's total annual
`revenue.
`Total Pharmaceutical Revenue in 2009: $10.4 million
`Sponsorship: $3.8 million
`Grants: $2.5 million
`Advertising: $1 million
`Total contribution by companies without an MS product on
`market in 2009: $3.1 million
`Total contribution by company with an MS product on
`market in 2009:
`
`http://www.ms-coalition.org/emergingtherapies/disclosures/organization-disclosures
`
`7/9
`
`MYLAN PHARMS. INC. EXHIBIT 1128 PAGE 7
`
`
`
`3/6/2016
`
`Organization Disclosures
`
`Bayer: $697,662
`Biogen Idec: $1,096,987
`EMD Serono/Pfizer: $2,853,514
`Novartis: $179,000
`Teva: $1,542,699
`
`Corporate Support: Corporations across the country support
`the mission through direct financial support, causerelated or
`valueadd partnerships, and even through significant probono
`services. Direct corporate support of approximately $2 million in
`2009, rounds out the remainder of the Society's total annual
`revenue.
`
`United Spinal Association
`2010 United Spinal Association is a 501(c)(3) membership
`organization that is dedicated to improving the lives of
`individuals with spinal cord injuries and disorders. Since 1946,
`United Spinal Association has encouraged its members and the
`larger community of all people with mobility disabilities to
`maximize their community integration and has worked to
`eliminate barriers that impede that goal. Through robust
`advocacy, communications, education and direct service
`programs, United Spinal removes physical, legislative, medical
`and attitudinal barriers that impede our members' independence
`and or quality of life.
`
`Access to our programs and services is available online, in print,
`through our tollfree helpline and through a variety of seminars
`and events held throughout the year.
`
`To achieve our mission, United Spinal Association receives
`support from the following sources:
`Individual Giving
`Bequests
`Programs and Services
`Donated Services and Facilities
`Pharmaceutical Revenue*
`Other
`Total Contributions:
`
`(68.9%)
`$12.2M
`(1.7%)
`$ 0.3M
`(10.2%)
`$ 1.8M
`(18.1%)
`$ 3.2M
`>$ 0.05M (<0.2%)
`$ 0.2M
`(1.1%)
`$17.7M
`
`* United Spinal Association participated in Allergan's Open
`Arms Campaign, promoting Botox© for use with patients with
`Upper Limb Spasticity.
`
`VA Centers of Excellence – East and West
`2010
`
`http://www.ms-coalition.org/emergingtherapies/disclosures/organization-disclosures
`
`8/9
`
`MYLAN PHARMS. INC. EXHIBIT 1128 PAGE 8
`
`
`
`3/6/2016
`
`Organization Disclosures
`The Veterans Administration and the MS Centers of Excellence
`are prohibited from receiving funds or other forms of support
`from industry or any entity doing business with the US federal
`government.
`
`
`
`Powered by Joomla!
`
`http://www.ms-coalition.org/emergingtherapies/disclosures/organization-disclosures
`
`9/9
`
`MYLAN PHARMS. INC. EXHIBIT 1128 PAGE 9